Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 20Neoplasms 9Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Malignancies 1Recurrence 1Pancreatic Neoplasms 1Lung Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma 1Advanced Solid Tumors 1Adenocarcinoma Of Esophagus 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × ixabepilone × Clear all
NCT01416389 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

Eli Lilly and Company

Phase 2 Completed
39 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡